Abstract
Serial analysis of gene expression followed by pathway analysis implicated the tight junction protein claudin-1 (CLDN1) in melanoma progression. Tight junction proteins regulate the paracellular transport of molecules, but staining of a tissue microarray revealed that claudin-1 was overexpressed in melanoma, and aberrantly expressed in the cytoplasm of malignant cells, suggesting a role other than transport. Indeed, melanoma cells in culture demonstrate no tight junction function. It has been shown that protein kinase C (PKC) can affect expression of claudin-1 in rat choroid plexus cells, and we observed a correlation between levels of activated PKC and claudin expression in our melanoma cells. To determine if PKC could affect the expression of CLDN1 in human melanoma, cells lacking endogenous claudin-1 were treated with 200 nM phorbol myristic acid (PMA). PKC activation by PMA caused an increase in CLDN1 transcription in 30 min, and an increase in claudin-1 protein by 12 h. Inhibition of PKC signaling in cells with high claudin-1 expression resulted in decreased claudin-1 expression. CLDN1 appears to contribute to melanoma cell invasion, as transient transfection of melanoma cells with CLDN1 increased metalloproteinase 2 (MMP-2) secretion and activation, and subsequently, motility of melanoma cells as demonstrated by wound-healing assays. Conversely, knockdown of CLDN1 by siRNA resulted in the inhibition of motility, as well as decreases in MMP-2 secretion and activation. These data implicate claudin-1 in melanoma progression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bartolome RA, Molina-Ortiz I, Samaniego R, Sanchez-Mateos P, Bustelo XR, Teixido J . (2006). Activation of Vav/Rho GTPase signaling by CXCL12 controls membrane-type matrix metalloproteinase-dependent melanoma cell invasion. Cancer Res 66: 248–258.
Betanzos A, Huerta M, Lopez-Bayghen E, Azuara E, Amerena J, Gonzalez-Mariscal L . (2004). The tight junction protein ZO-2 associates with Jun, Fos and C/EBP transcription factors in epithelial cells. Exp Cell Res 292: 51–66.
Cohn ML, Goncharuk VN, Diwan AH, Zhang PS, Shen SS, Prieto VG . (2005). Loss of claudin-1 expression in tumor-associated vessels correlates with acquisition of metastatic phenotype in melanocytic neoplasms. J Cutan Pathol 32: 533–536.
D'Souza T, Agarwal R, Morin PJ . (2005). Phosphorylation of claudin-3 at threonine 192 by cAMP-dependent protein kinase regulates tight junction barrier function in ovarian cancer cells. J Biol Chem 280: 26233–26240.
da Rocha AB, Mans DR, Lenz G, Fernandes AK, de Lima C, Monteiro VF et al. (2000). Protein kinase C-mediated in vitro invasion of human glioma cells through extracellular-signal-regulated kinase and ornithine decarboxylase. Pathobiology 68: 113–123.
Dhawan P, Singh AB, Deane NG, No Y, Shiou SR, Schmidt C et al. (2005). Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest 115: 1765–1776.
Dumont JA, Jones Jr WD, Bitonti AJ . (1992). Inhibition of experimental metastasis and cell adhesion of B16F1 melanoma cells by inhibitors of protein kinase C. Cancer Res 52: 1195–1200.
Furuse M, Hata M, Furuse K, Yoshida Y, Haratake A, Sugitani Y et al. (2002). Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J Cell Biol 156: 1099–1111.
Gonzalez-Mariscal L, Betanzos A, Nava P, Jaramillo BE . (2003). Tight junction proteins. Prog Biophys Mol Biol 81: 1–44.
Heiskala M, Peterson PA, Yang Y . (2001). The roles of claudin superfamily proteins in paracellular transport. Traffic 2: 93–98.
Lippoldt A, Liebner S, Andbjer B, Kalbacher H, Wolburg H, Haller H et al. (2000). Organization of choroid plexus epithelial and endothelial cell tight junctions and regulation of claudin-1, -2 and -5 expression by protein kinase C. Neuroreport 11: 1427–1431.
Miyamori H, Takino T, Kobayashi Y, Tokai H, Itoh Y, Seiki M et al. (2001). Claudin promotes activation of pro-matrix metalloproteinase-2 mediated by membrane-type matrix metalloproteinases. J Biol Chem 276: 28204–28211.
Morin PJ . (2005). Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 65: 9603–9606.
Nakamura K, Yoshikawa N, Yamaguchi Y, Kagota S, Shinozuka K, Kunitomo M . (2003). Effect of PKC412, an inhibitor of protein kinase C, on spontaneous metastatic model mice. Anticancer Res 23: 1395–1399.
Oku N, Sasabe E, Ueta E, Yamamoto T, Osaki T . (2006). Tight junction protein claudin-1 enhances the invasive activity of oral squamous cell carcinoma cells by promoting cleavage of laminin-5 gamma2 chain via matrix metalloproteinase (MMP)-2 and membrane-type MMP-1. Cancer Res 66: 5251–5257.
Park MJ, Park IC, Lee HC, Woo SH, Lee JY, Hong YJ et al. (2003). Protein kinase C-alpha activation by phorbol ester induces secretion of gelatinase B/MMP-9 through ERK 1/2 pathway in capillary endothelial cells. Int J Oncol 22: 137–143.
Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM et al. (2003). High frequency of BRAF mutations in nevi. Nat Genet 33: 19–20.
Rangel LB, Agarwal R, D'Souza T, Pizer ES, Alo PL, Lancaster WD et al. (2003). Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 9: 2567–2575.
Sawada N, Murata M, Kikuchi K, Osanai M, Tobioka H, Kojima T et al. (2003). Tight junctions and human diseases. Med Electron Microsc 36: 147–156.
Smalley KS, Brafford P, Haass NK, Brandner JM, Brown E, Herlyn M . (2005). Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. Am J Pathol 166: 1541–1554.
Swisshelm K, Macek R, Kubbies M . (2005). Role of claudins in tumorigenesis. Adv Drug Deliv Rev 57: 919–928.
Weeraratna AT, Becker D, Carr KM, Duray PH, Rosenblatt KP, Yang S et al. (2004). Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome. Oncogene 23: 2264–2274.
Weeraratna AT, Jiang Y, Hostetter G, Rosenblatt K, Duray P, Bittner M et al. (2002). Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1: 279–288.
Acknowledgements
We thank Drs Michel Bernier, Vishwa Deep-Dixit, Teresa D'Souza and Rachana Agarwal for helpful discussion, reagents and technical advice. We thank Dr Meenhard Herlyn for his generous gift of cell lines, and Ms Ana Lustig for help with the pathway analysis software. We thank Drs Jeff Trent, Michael Bittner, Galen Hostetter and Urs Wagner for the melanoma tissue microarray. We also thank Mr Jason Godlove for help with statistical analysis. This work was supported by funding from the Intramural Research Program of the National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Supplementary information
Rights and permissions
About this article
Cite this article
Leotlela, P., Wade, M., Duray, P. et al. Claudin-1 overexpression in melanoma is regulated by PKC and contributes to melanoma cell motility. Oncogene 26, 3846–3856 (2007). https://doi.org/10.1038/sj.onc.1210155
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210155
Keywords
This article is cited by
-
Claudin 1, 4 and 7 Expression in Malignant Melanoma
Indian Journal of Surgery (2023)
-
Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer
World Journal of Urology (2020)
-
Tight junction proteins at the blood–brain barrier: far more than claudin-5
Cellular and Molecular Life Sciences (2019)
-
Antibody targeting of claudin-1 as a potential colorectal cancer therapy
Journal of Experimental & Clinical Cancer Research (2017)
-
Serglycin in tumor microenvironment promotes non-small cell lung cancer aggressiveness in a CD44-dependent manner
Oncogene (2017)